Prognostic value of pre-treatment DCE-MRI parameters in predicting disease free and overall survival for breast cancer patients undergoing neoadjuvant chemotherapy.

[1]  D. Balvay,et al.  Tumor angiogenesis: pathophysiology and implications for contrast-enhanced MRI and CT assessment , 2006, Abdominal Imaging.

[2]  S. Matsumoto,et al.  Prognostic value of dynamic MR imaging for non‐small‐cell lung cancer patients after chemoradiotherapy , 2005, Journal of magnetic resonance imaging : JMRI.

[3]  L. Turnbull,et al.  Role of dynamic contrast enhanced MRI in monitoring early response of locally advanced breast cancer to neoadjuvant chemotherapy , 2005, Breast Cancer Research and Treatment.

[4]  S. Giordano,et al.  Update on locally advanced breast cancer. , 2003, The oncologist.

[5]  B. Szabó,et al.  Can contrast-enhanced MR imaging predict survival in breast cancer? , 2003, Acta radiologica.

[6]  Herman Depypere,et al.  Assessment of response to preoperative chemotherapy in patients with stage II and III breast cancer: the value of MRI , 2002 .

[7]  A. Padhani,et al.  Assessing changes in tumour vascular function using dynamic contrast‐enhanced magnetic resonance imaging , 2002, NMR in biomedicine.

[8]  C. V. D. van de Velde,et al.  Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  P J Drew,et al.  Evaluation of response to neoadjuvant chemoradiotherapy for locally advanced breast cancer with dynamic contrast-enhanced MRI of the breast. , 2001, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[10]  W. Reddick,et al.  Dynamic magnetic resonance imaging of regional contrast access as an additional prognostic factor in pediatric osteosarcoma , 2001, Cancer.

[11]  G Brix,et al.  Pathophysiologic basis of contrast enhancement in breast tumors , 1999, Journal of magnetic resonance imaging : JMRI.

[12]  R Musumeci,et al.  Locally Advanced Breast Cancer Treated with Primary Chemotherapy: Comparison between Magnetic Resonance Imaging and Pathologic Evaluation of Residual Disease , 1999, Tumori.

[13]  M V Knopp,et al.  Angiogenic activity of cervical carcinoma: assessment by functional magnetic resonance imaging-based parameters and a histomorphological approach in correlation with disease outcome. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[14]  G Brix,et al.  Uterine cervical carcinoma: comparison of standard and pharmacokinetic analysis of time-intensity curves for assessment of tumor angiogenesis and patient survival. , 1998, Cancer research.

[15]  G Brix,et al.  Angiogenesis of uterine cervical carcinoma: characterization by pharmacokinetic magnetic resonance parameters and histological microvessel density with correlation to lymphatic involvement. , 1997, Cancer research.

[16]  O. Vinante,et al.  Prognostic significance of vascular endothelial growth factor protein in node-negative breast carcinoma. , 1997, Journal of the National Cancer Institute.

[17]  R. Gilles,et al.  Locally advanced breast cancer: contrast-enhanced subtraction MR imaging of response to preoperative chemotherapy. , 1994, Radiology.

[18]  L R Schad,et al.  Pharmacokinetic parameters in CNS Gd-DTPA enhanced MR imaging. , 1991, Journal of computer assisted tomography.

[19]  L. Liotta,et al.  Quantitative relationships of intravascular tumor cells, tumor vessels, and pulmonary metastases following tumor implantation. , 1974, Cancer research.